Latest News
Feb 20, 2018

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced receipt of tentative approval from the U.S. Food and Drug Administration (FDA) under the U.S. President's Emergency Plan for...

Feb 8, 2018

Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will release its fourth quarter and full year 2017 financial results, as well as its 2018 financial guidance, on Wednesday, Feb. 28,...

Feb 1, 2018

Global pharmaceutical leader Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Efavirenz Tablets USP, 600 mg, the first generic version of Bristol-Myers Squibb's Sustiva®. The...

Jan 29, 2018

Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced that the U.S. Food and Drug Administration (FDA) has accepted for...

Jan 29, 2018

Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued...

View More


Search News Releases

Contact Mylan Communications

Global Communications 
724.514.1968
communications@mylan.com

Stay Connected